pentamidine (Q416206)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

chemical compound

RP-2512 [as isethionate]
Pentam
Nebupent [as isethionate]
MB-800 [as isethionate]
MB-800
Pentacarinat [as isethionate]
RP-2512
GNF-Pf-3680
Pentam 300 [as isethionate]
Pentam 300
1,5-Bis(4-amidinophenoxy)pentane
Pentamidindiisetionat
4,4'-Diamidinodiphenoxypentane
4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(Pentamethylenedioxy)dibenzamidine
P,P'-(pentamethylenedioxy)dibenzamidine
Pentamidin
Pentamidina
Pentamidine
Pentamidinum

Language	Label	Description	Also known as
English	pentamidine	chemical compound	RP-2512 [as isethionate] Pentam Nebupent [as isethionate] MB-800 [as isethionate] MB-800 Pentacarinat [as isethionate] RP-2512 GNF-Pf-3680 Pentam 300 [as isethionate] Pentam 300 1,5-Bis(4-amidinophenoxy)pentane Pentamidindiisetionat 4,4'-Diamidinodiphenoxypentane 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide 4,4'-(Pentamethylenedioxy)dibenzamidine P,P'-(pentamethylenedioxy)dibenzamidine Pentamidin Pentamidina Pentamidine Pentamidinum

Statements

type of chemical entity

0 references

chemical compound

0 references

1 reference

Pentamidine (English)

language of work or name

publication date

17 November 2015

chemical structure

Pentamidine-skeletal.svg
512 × 135; 6 KB

0 references

340.19 dalton

1 reference

language of work or name

pentamidine (English)

17 November 2016

chemical formula

C₁₉H₂₄N₄O₂

1 reference

language of work or name

pentamidine (English)

17 November 2016

canonical SMILES

C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N

1 reference

language of work or name

pentamidine (English)

17 November 2016

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

pentamidine (English)

1 reference

language of work or name

pentamidine (English)

19 October 2016

medical condition treated

parasitic protozoa infectious disease

1 reference

language of work or name

13 December 2016

visceral leishmaniasis

1 reference

language of work or name

13 December 2016

trypanosomiasis

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

arsenic trioxide

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

(RS)-citalopram

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

bone marrow failure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

bone marrow failure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sulfamethoxazole

bone marrow failure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

bone marrow failure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sulfamethoxazole

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sulfamethoxazole

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sulfamethoxazole

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sulfamethoxazole

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pregnancy category

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

subject has role

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

trypanocidal agent

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

1 reference

Commons category

Pentamidine

0 references

Identifiers

InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)

1 reference

language of work or name

pentamidine (English)

17 November 2016

XDRYMKDFEDOLFX-UHFFFAOYSA-N

2 references

language of work or name

pentamidine (English)

17 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

XDRYMKDFEDOLFX-UHFFFAOYSA-N

CAS Common Chemistry

8 April 2021

https://commonchemistry.cas.org/detail?cas_rn=100-33-4

1 reference

language of work or name

pentamidine (English)

17 November 2016

2 references

language of work or name

pentamidine (English)

17 November 2016

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

Reaxys registry number

3159790

1 reference

language of work or name

pentamidine (English)

19 October 2016

mapping relation type

2 references

language of work or name

PENTAMIDINE (English)

17 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)

1 reference

language of work or name

PENTAMIDINE (English)

17 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

UniChem compound ID

1 reference

MassBank accession ID

MSBNK-Fiocruz-FIO00450

0 references

MSBNK-Fiocruz-FIO00451

0 references

MSBNK-Fiocruz-FIO00452

0 references

MSBNK-Fiocruz-FIO00453

0 references

MSBNK-Fiocruz-FIO00454

0 references

MSBNK-Keio_Univ-KO003937

0 references

MSBNK-Keio_Univ-KO003938

0 references

MSBNK-Keio_Univ-KO003939

0 references

MSBNK-Keio_Univ-KO003940

0 references

MSBNK-Keio_Univ-KO003941

0 references

MSBNK-Keio_Univ-KO009179

0 references

MSBNK-Keio_Univ-KO009180

0 references

MSBNK-Keio_Univ-KO009181

0 references

splash10-0006-0009000000-18ffa88d8e83e0c224b3

0 references

splash10-00di-0309000000-22a206e2fffa6ce5cf2f

0 references

splash10-00dr-0900000000-d135e9c44dbf5da10735

0 references

splash10-00di-0900000000-d01e29cdf614c3660180

0 references

splash10-0006-0009000000-1499530d0d768e480fd7

0 references

splash10-0006-0009000000-3c60569ced478a95001f

0 references

splash10-00di-0209000000-58a168dde59140860009

0 references

splash10-00dr-0901000000-7cd36861b140e4e5a6a2

0 references

splash10-00di-0900000000-60dfcd75868e869bcbf7

0 references

splash10-00di-0009000000-6677c6c06aa266d05ff1

0 references

splash10-00dr-0903000000-140ddf0bc9583ef7ea2b

0 references

splash10-00kr-6900000000-e0a164c7a34de0798880

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

PENTAMIDINE (English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

1 reference

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Pentamidine (English)

CAS no.: 100-33-4 (English)

MeSH descriptor ID

subject named as

Pentamidine

0 references

MeSH concept ID

0 references

D02.078.100.700

0 references

1 reference

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

1 reference

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

matched by identifier from

XDRYMKDFEDOLFX-UHFFFAOYSA-N

MedlinePlus drug identifier

route of administration

intramuscular injection

intravenous injection

0 references

route of administration

inhalation administration

0 references

1 reference

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

pentamidine (English)

19 October 2016

0 references

electronic Essential Medicines List medicine ID

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3GY3 (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

1D64 (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3HII (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3CR4 (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3CR5 (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

1RKW (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3EY0 (English)

19 October 2016

1 reference

Global Substance Registration System

language of work or name

pentamidine (English)

17 November 2016

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(21 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Pentamidine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q416206&oldid=2186734407"